PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor

Shakib, Zahra; Mahmoudi, Asma; Moosavian, Seyedeh Alia; Malaekeh‐Nikouei, Bizhan

doi:10.1080/03639045.2022.2095398

Cited by 10 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the unconvincing in vivo results of antibody-conjugated liposomes leave researchers looking for alternatives, and aptamers offer several advantages over antibodies that have led to an increased interest. Currently, aptamer-conjugated liposomes have been used in research to selectively bind and deliver drugs to a variety of tissues [ 117 ], including cancer cells [ 118 , 119 , 120 , 121 ], corneal cells [ 122 ], muscle tissue [ 123 ], and intestinal epithelia [ 124 ]. For the most part, these liposomes have fared well during in vivo studies as compared to antibody-conjugated liposomes.…”

Section: Active Targeted Liposomesmentioning

confidence: 99%

Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges

Gatto,

Johnson,

Najahi-Missaoui

2024

Life

View full text Add to dashboard Cite

In drug development, it is not uncommon that an active substance exhibits efficacy in vitro but lacks the ability to specifically reach its target in vivo. As a result, targeted drug delivery has become a primary focus in the pharmaceutical sciences. Since the approval of Doxil® in 1995, liposomes have emerged as a leading nanoparticle in targeted drug delivery. Their low immunogenicity, high versatility, and well-documented efficacy have led to their clinical use against a wide variety of diseases. That being said, every disease is accompanied by a unique set of physiological conditions, and each liposomal product must be formulated with this consideration. There are a multitude of different targeting techniques for liposomes that can be employed depending on the application. Passive techniques such as PEGylation or the enhanced permeation and retention effect can improve general pharmacokinetics, while active techniques such as conjugating targeting molecules to the liposome surface may bring even further specificity. This review aims to summarize the current strategies for targeted liposomes in the treatment of diseases.

show abstract

Section: Active Targeted Liposomesmentioning

confidence: 99%

Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges

Gatto,

Johnson,

Najahi-Missaoui

2024

Life

View full text Add to dashboard Cite

show abstract

“…Due to high loading capacity, NPs can reduce dosing frequency and improve patient compliance [6]. Based on these features, a great number of NPs were engineered for cancer research, generating positive results in animal models [7][8][9][10]. Some nanoscale formulations exhibiting promising outcomes in clinical trials have been approved for clinical cancer treatments.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in nano/micro systems for improved circulation stability, enhanced tumor targeting, penetration, and intracellular drug delivery: a review

Chan,

2024

Biomed. Phys. Eng. Express

View full text Add to dashboard Cite

In recent years, nanoparticles (NPs) have been extensively developed as drug carriers to overcome the limitations of cancer therapeutics. However, there are several challenges to nanomedicines, which include the lack of stability in circulation, limited target specificity, low penetration into tumors and insufficient cellular uptake, restricting the active targeting toward tumors of nanomedicines. To address these challenges, a variety of promising strategies were developed recently, as they can be designed to improve NP accumulation and penetration in tumor tissues, circulation stability, tumor targeting, and intracellular uptake. In this Review, we summarized nanomaterials developed in recent three years that could be utilized to improve drug delivery for cancer treatments.

show abstract

“…If not appropriately functionalized, the opsonin protein within the blood will absorb the NPs and be removed from the circulatory system by macrophages [ 24 , 25 ]. Polyethylene glycol (PEG) has been demonstrated in numerous studies to be an effective conjugation to NPs to increase the blood circulation time, which subsequently contributes to a greater possibility of tumour penetration via the enhanced permeability and retention (EPR) effect [ 26 , 27 , 28 , 29 , 30 , 31 ]. EPR is the process by which small molecules preferentially invade tumour tissue based on its poor structural integrity and leaky endothelial conjunction [ 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

“…Targeting components within the TME may achieve the improved cellular uptake of nanoparticle radiosensitizers and other cytotoxic drug compounds (Figure 1). blood circulation time, which subsequently contributes to a greater possibility of tumour penetration via the enhanced permeability and retention (EPR) effect [26][27][28][29][30][31]. EPR is the process by which small molecules preferentially invade tumour tissue based on its poor structural integrity and leaky endothelial conjunction [32,33].…”

Section: Introductionmentioning

confidence: 99%

Improving the Efficacy of Common Cancer Treatments via Targeted Therapeutics towards the Tumour and Its Microenvironment

Cecchi,

Jackson,

Beckham

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cancer is defined as the uncontrolled proliferation of heterogeneous cell cultures in the body that develop abnormalities and mutations, leading to their resistance to many forms of treatment. Left untreated, these abnormal cell growths can lead to detrimental and even fatal complications for patients. Radiation therapy is involved in around 50% of cancer treatment workflows; however, it presents significant recurrence rates and normal tissue toxicity, given the inevitable deposition of the dose to the surrounding healthy tissue. Chemotherapy is another treatment modality with excessive normal tissue toxicity that significantly affects patients’ quality of life. To improve the therapeutic efficacy of radiotherapy and chemotherapy, multiple conjunctive modalities have been proposed, which include the targeting of components of the tumour microenvironment inhibiting tumour spread and anti-therapeutic pathways, increasing the oxygen content within the tumour to revert the hypoxic nature of the malignancy, improving the local dose deposition with metal nanoparticles, and the restriction of the cell cycle within radiosensitive phases. The tumour microenvironment is largely responsible for inhibiting nanoparticle capture within the tumour itself and improving resistance to various forms of cancer therapy. In this review, we discuss the current literature surrounding the administration of molecular and nanoparticle therapeutics, their pharmacokinetics, and contrasting mechanisms of action. The review aims to demonstrate the advancements in the field of conjugated nanomaterials and radiotherapeutics targeting, inhibiting, or bypassing the tumour microenvironment to promote further research that can improve treatment outcomes and toxicity rates.

show abstract

PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor

Cited by 10 publications

References 39 publications

Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges

Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges

Recent advances in nano/micro systems for improved circulation stability, enhanced tumor targeting, penetration, and intracellular drug delivery: a review

Improving the Efficacy of Common Cancer Treatments via Targeted Therapeutics towards the Tumour and Its Microenvironment

Contact Info

Product

Resources

About